The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A L updates comparison of cardiac resynchronization therapy implantation practice in Europe and France

Background. - The first European Cardiac Resynchronization Therapy (CRT) Survey, conducted in 2008-2009, showed considerable variations in guideline adherence and implantation practice. A second prospective survey (CRT Survey II) was then performed to describe contemporary clinical practice regarding CRT among 42 European countries. Aim. - To compare the characteristics of French CRT recipients with the overall population of CRT Survey II. Methods. - Demographic and procedural data from French centres recruiting all consecutive patients undergoing either de novo CRT implantation or an upgrade to a CRT system were collected and compared with data from the European population. Results. - A total of 11,088 patients were enrolled in CRT Survey II, 754 of whom were recruited in France. French patients were older (44.7% aged >= 75 years vs 31.1% in the European group), had less severe heart failure symptoms, a higher baseline left ventricular ejection fraction and fewer co-morbidities. Additionally, French patients had a shorter intrinsic QRS duration (19.1% had a QRS < 130 ms vs 12.3% in the European cohort). Successful implantation rates were similar, but procedural and fluoroscopy times were shorter in France. French patients were more likely to receive a CRT pacemaker than European patients overall. Of note, antibiotic prophylaxis was reported to be administered less frequently in France, and a higher rate of early device-related infection was observed. Importantly, French patients were less likely to receive optimal drugs for treating heart failure at hospital discharge. Conclusion. - This study highlights contemporary clinical practice in France, and describes sub- stantial differences in patient selection, implantation procedure and outcomes compared with the other European countries participating in CRT Survey II. (C) 2019 Published by Elsevier Masson SAS.